IL2 and neoplasm: This is also the first observation that the administration of TKD/IL-2-activated PBMNC induces a sustained in vivo NK cell cytolytic response against the patient's own, Hsp70 membrane-positive tumor and the classical NK cell target K562 which persists for at least 2 months.